Evaluation of Mucociliary Clearance by Three Dimension Micro-CT-SPECT in Guinea Pig: Role of Bitter Taste Agonists

Jose Luis Ortiz¹, Amparo Ortiz¹, Javier Milara²,³,⁴*, Miguel Armengot⁵,⁶, Celia Sanz¹,², Desamparados Compañª, Esteban Morcillo¹,⁴, Julio Cortijo¹,⁴,⁸

¹ Department of Pharmacology, Faculty of Medicine, University of Valencia, Valencia, Spain, ² Jaume I University, faculty of Medicine, Castellón, Spain, ³ Department of Pharmacy, University General Hospital Consortium, Valencia, Spain, ⁴ CIBERES, Health Institute Carlos III, Valencia, Spain, ⁵ Rhinology Unit, University General Hospital Consortium, Valencia, Spain, ⁶ Department of Surgery, Faculty of Medicine, University of Valencia, Valencia, Spain, ⁷ Pathological Anatomy Department, Hospital Clínic Universitari of Valencia, Valencia, Spain, ⁸ Teaching and Research Unit, University General Hospital Consortium, Valencia, Spain

* xmilara@hotmail.com

Abstract

Different image techniques have been used to analyze mucociliary clearance (MCC) in humans, but current small animal MCC analysis using in vivo imaging has not been well defined. Bitter taste receptor (T2R) agonists increase ciliary beat frequency (CBF) and cause bronchodilation but their effects in vivo are not well understood. This work analyzes in vivo nasal and bronchial MCC in guinea pig animals using three dimension (3D) micro-CT-SPECT images and evaluates the effect of T2R agonists. Intranasal macroaggregates of albumin-Technetium 99 metastable (MAA-Tc99m) and lung nebulized Tc99m albumin nanocolloids were used to analyze the effect of T2R agonists on nasal and bronchial MCC respectively, using 3D micro-CT-SPECT in guinea pig. MAA-Tc99m showed a nasal mucociliary transport rate of 0.36 mm/min that was increased in presence of T2R agonist to 0.66 mm/min. Tc99m albumin nanocolloids were homogeneously distributed in the lung of guinea pig and cleared with time-dependence through the bronchi and trachea of guinea pig. T2R agonist increased bronchial MCC of Tc99m albumin nanocolloids. T2R agonists increased CBF in human nasal ciliated cells in vitro and induced bronchodilation in human bronchi ex vivo. In summary, T2R agonists increase MCC in vivo as assessed by 3D micro-CT-SPECT analysis.

Introduction

The airways are constantly challenged by inhaled microbial pathogens. Mucociliary clearance (MCC) is the primary physical defense against inhaled pathogens, toxins and particulates in the respiratory system. Appropriate mucus production and coordinated ciliary activity are the premises for effective clearance.
There are many reasons why MCC could be impaired. The movements of the cilia can be hindered directly as occurs in cilia genetic disorders (primary ciliary dyskinesia) or by temporary dysfunction caused by airway infection or environmental influences [1–3]. The mucus layer can constitute the main problem when dehydration of the mucus leads to increased viscosity whereby the ciliary clearance becomes ineffective [4, 5]. In chronic airway diseases, hypersecretion of mucin leads to excessive amounts of mucus with an increased viscosity that is hard to clear from the airways and in severe cases can end up forming mucus plugs whereby infection or localized atelectasis can be observed [5, 6].

Eventually, the inflammation generated by defects in MCC can lead to bronchiectasis characterized by permanent dilation of the airway and thickening of the bronchial wall [7]. All severe chronic diseases involving defective MCC result in substantial morbidity in terms of dyspnoea, recurring sinopulmonary infections, and frequent and productive coughs. The close relationship with infection is also evident in patients with acute infectious exacerbation of chronic obstructive pulmonary disease where large amounts of viscous sputum are produced [5]. In this regard, many new therapies directed to improve MCC are currently under research, including those directed to increase ciliary beat frequency (CBF), to reduce mucus secretion or mucus viscosity, with the final objective to improve morbidity and clinical symptoms of upper and lower chronic lung diseases [8].

Several technologies have been developed to monitor MCC. Thus for example, inhaled radioaerosols containing insoluble technetium 99m metastable (Tc99m) labelled colloids have been employed to monitor MCC by scintigraphy. This technique has been used for many years to evaluate human pulmonary clearance studies, reflecting the combination of MCC, cough clearance or the combination of both [9], thus assessing a possible link between mucociliary dysfunction and pathophysiology of lung diseases or pharmacological challenges to the mucociliary apparatus. However, different variations of radiocolloids (albumin/sulphur particles), particle size selection, inhalation technique, gamma camera acquisition (static/dynamic/ single-photon emission computerized tomography (SPECT)), particle deposition (nasal deposition, low airways deposition), reflects the difficulties of technique application and that the choice of ‘best’ method depends upon the specific aim of the test. Furthermore, small animal MCC analysis using radiocolloid imaging has not been well explored which may limit MCC preclinical research.

The present work analyzes different radiocolloid animal three dimension (3D) micro-computer tomography (CT)-SPECT techniques, to study nasal and bronchial MCC as a potential tool to evaluate MCC abnormalities as well as new pharmacological therapies directed to improve MCC in chronic airway disorders. To this end we characterized different bitter taste-sensing receptor (T2Rs) agonists on MCC in in vivo animal micro-CT-SPECT radionuclear models. T2Rs activation increase CBF [10] and bronchodilation [11] providing an optimal control to characterize in vivo MCC techniques. The effect T2Rs agonists on in vitro CBF using high speed video-microscopy and ex vivo bronchial relaxation in organ baths were also analyzed to corroborate in vivo analysis. Results obtained in this study provides different pre-clinical models to characterizes MCC which may be of potential value to the study of different upper and lower respiratory diseases as well as to evaluate new therapies directed to improve MCC.

**Methods**

**Animal experiments**

Experimentation and handling were performance in accordance with the guidelines of the Committee of Animal Ethics and Well-being of the University of Valencia (Valencia, Spain).
Animal studies used pathogen-free male Guinea pig (Harlan Iberica®, Barcelona, Spain) at 12 weeks of age. Guinea pig were housed with free access to water and food under standard conditions: relative humidity 55 ± 10%; temperature 22 ± 3°C; 15 air cycles/ per hour; 12/12 h Light/Dark cycle.

**Nasal mucociliary transport rate (NMTR) measurement in guinea pig.** Guinea pig animals (~350 g) were anesthetized with intraperitoneal mixture of ketamin (70 mg/Kg) and medetomidin (0.25 mg/kg). After a period of 10 min, the animals were placed into double-chamber plethysmograph (DCP) with conical restrainer nose-only system adapted to guinea pig animals (250-400g animal; emka technologies, Paris, France). DCP was connected to a ventilation pump (model 683; Harvard Apparatus) to renewal of air inside the head chamber. A vacuum pump N0022AN.9E (KNF Neuberger, Freiburg, Germany) was connected to the chamber to draw out the air introduced by ventilator. Air from ventilator and vacuum pump were filtered through a 0.1μm PESU membrane filter (Sartorius stedium biotech, goettingen, Germany). The head unit of the DCP was connected to the nebulizer head unit (Aeroneb® Lab Nebulizer, Aerogen Inc. Galway, Ireland) provided with a filler cap. Nebulizer head unit was controlled with a nebulization-controller device (emka technologies, Paris, France). A final volume of 300μl with vehicle (phosphate buffer), T2Rs agonist chloroquine, denatonium or saccharine at 1 mM were deposited in the nebulizer head unit and nebulized to the nose-only system of the chamber head unit during 15 min. The flow rate of nebulization was controlled with the nebulization-controller device to provide a 15 min cycle of nebulization. The nebulization head emits a fine-droplet (mass median aerodynamic diameter < 3μm to 0.55 mm) aerosol at low velocity without heat and propellants and without pressure or volume fluctuations. No residual liquid remained in the head unit indicating a high efficiency. Considering that the trachea of guinea pigs with mean body weight of 400 g is a 3.51 ± 0.88 cm long and 0.21 ± 0.05 cm in diameter (mean ± SEM) and that the bronchioles, alveolar ducts, and alveolar sacs are about the same diameter (0.01 to 0.015 cm), and the alveoli are approximately 0.008 cm in diameter [12]) we can assume that nebulized solution reached the whole lung volume of guinea pig. So deposition site of the drugs was nose, tracheal, bronchial and alveolar units. In this setting, diameter of <3μm to 0.55 combine impaction and diffusion processes [13]. Drug solutions were dissolved in phosphate buffer solution adjusted to pH 7.4 since pH can affect cilia motility (acid pH decrease CBF) and bronchial contractility (acid pH increase bronchial contractility).

After vehicle/drug delivery, a suspension of albumin macroaggregated Tc99m (MAA-Tk99m) (Molipharma, Valencia Spain; 10 mCi; particle diameter 5–90μm) was intranasally instilled (one droplet of 25 μL) on the nasal meatus using a micropipette. The animals were introduced into the micro-CT-SPECT (Albira, Oncovision™, Valencia, Spain) in supine position in a cradle made of plexiglas, and dynamic capture of micro computer tomography (CT) and micro-SPECT images were acquired each 12 min during 60 min. The time of each capture was 1min (until 300000 counts). Head and neck images were taken as follow: planar scintigraphy in anterior (A), posterior (P) left and right lateral (LL and RL), and left and right posterior oblique (LPO and RPO) views. The images were reconstructed with filtered back projection algorithm using the Albira Suite 5.0 software (OncoVision, Valencia, Spain). The combination of acquisition and reconstruction result in a final whole image matrix of 255° 255° 255 mm with a pixel size of 0.25°0.25°0.25 mm. 252 image sections corresponding to the whole head and neck images (3D images) were acquired in each capture and analyzed with the PMOD™ software selecting a whole 3D volume of interest (VOI) after radioisotope administration (basal image). Nasal mucociliary transport rate (NMTR) was calculated measuring the distance (milimeters) reached by the front of MAA-Tc99m radioparticles signal in 1 min (mm/min). The experimental groups were control group (vehicle nebulization; n = 9) and test...
compound groups (chloroquine 1mM; n = 9; denatonium 1mM; n = 9, Saccharin 1mM; n = 9).
Drug concentrations were selected from previous studies as effective concentrations [11].

Bronchial mucociliary clearance analysis using ventilated Tc99m DTPA, intratracheal Tc99m albumin macroaggregates or ventilated Tc99m albumin nanocolloids in guinea pig. Guinea pig animals (~350 g) were anesthesized with intraperitoneal mixture of ketamin (70 mg/Kg) and medetomidin (0.25 mg/kg). After a period of 10 min, the animals were placed into double-chamber plethysmograph and drugs were nebulized as described in the NMTR section. After drug delivery, three different techniques were assayed to evaluate bronchial mucociliary clearance. 1) The animals were nebulized as described for the drugs with a solution containing 300μl diethylene-triamine-pentaacetate 10 mCi (DTPA-Tc99m) (Molipharma, Valencia, Spain) for 15 min. After DTPA-Tc99m delivery, the animals were removed from the nebulizer chamber and allowed to breathe freely. 2) MAA-Tc99m (100 μL; 10 mCi; particle diameter 5–90μm) particle suspension was intra-tracheally administered via the endotracheal route as previously outlined [14, 15]. 3) A suspension of Tc99m albumin nanocolloids (Molipharma, Valencia Spain; 10 mCi; particle diameter ≤80nm) was nebulized during 15 min as described for drugs.

For each of the three different radionuclear preparations SPECT dynamic scans were acquired each 4 min during the first 60 min, and punctual acquisitions at 2h, 4h and 6h time points on an ALBIRA micro-SPECT system (Oncovision®, Valencia, Sapin) using pinhole collimators and a radius of rotation of 3.5 cm. Micro-CT images were acquired to locate radioisotope signal in animal lungs. The time of each capture was 1min (until 300000 counts). Lung images were taken as follow: planar scintigraphy in anterior (A), posterior (P) left and right lateral (LL and RL), and left and right posterior oblique (LPO and RPO) views. The images were reconstructed with filtered back projection algorithm using the Albira Suite 5.0 software (OncoVision, Valencia, Spain). The combination of acquisition and reconstruction result in a final whole image matrix of 255 x 255 x 255 mm with a pixel size of 0.25 x 0.25 x 0.25 mm. 252 image sections corresponding to the whole lung (3D images) were acquired in each capture and analyzed with the PMOD™ software selecting a whole 3D VOI after radioisotope administration (basal image). During dynamic capture the animals were anesthetized. All scans were performed with gamma cameras with large field-of-view detectors, equipped with low energy general purpose collimators. The analysis of MCC was performed with the PMOD™ software selecting a whole 3D VOI after radioisotope administration (basal image) and repeating measures at different times applying the same VOI. Quantification was performed by analyzing the number of counts in the same VOI applied to every image (counts per pixel unit) corrected for the radioactive decay of Tc99m. Computerized tomography (CT) images were captured to visualize the anatomic location of the SEPCT images. The experimental groups are defined as control group (phosphate buffer vehicle ventilation; n = 12) and test compound group (Chloroquine 1mM; n = 12; Denatonium 1mM; n = 12, Saccharin 1mM; n = 12). Bronchial MCC was calculated in each individual as the % of the lost of radiation counts on the whole VOI at each time point during the 6h period being 100% of signal the SPECT acquisition at time 0 min.

Human experiments

Samples of nasal epithelial cells were obtained from adult healthy subjects, free of airway infections, by curettage of middle turbinate mucosa without the use of local anaesthesia to avoid any external influence as previously outlined [16]. Lung tissue was obtained from patients who were undergoing surgery for lung carcinoma. Bronchial isolation was obtained in healthy tissue as far from the tumor lesion as previously outlined [17]. The protocol was approved by the
local research and independent ethics committee of the University General Consortium Hospital of Valencia (CEIC25/2015). Informed written consent was obtained from each participant.

**Measurement of ciliary beat frequency in human nasal epithelial cells.** Nasal epithelial cells from middle turbinate mucosa were introduced into 1 ml of Dulbecco's modified Eagle's medium (DMEM, Cambrex) supplemented with 10% foetal bovine serum, 2 mM glutamine, penicillin (100 U/ml) and streptomycin (100 mg/ml). The nasal biopsy was partially disaggregated and dissolved in this medium. Culture dishes treated with 0.5% gelatine (Corning Incorporated Costar 3513, 12-wells) to facilitate adherence of ciliated cells were used to grow 150 μl samples of nasal epithelium biopsies as previously outlined [16]. The study was conducted between 23°C and 27°C room temperature. Measurement of CBF and functional ciliated cell analysis followed previously described protocols [16]. Briefly, cells were imaged with a digital high speed video (DHSV) imaging technique using a Nikon Eclipse TS100 microscope equipped with a 40x Nikon phase-contrast objective. Contrast enhanced video images were selected and the light intensity of the selected pixels was recorded on a frame-by-frame basis. In addition, the magnitude spectrum from a fast Fourier transformation of the variation of pixel intensity signal was analysed in an average of six different regions of (3 x 3 pixels) the cilia in individual cells in a minimum of 10 cells per experiment. CBF experiments were performed with cells submerged in Hanks' Balanced Salt Soln (HBSS) (Lonza, Cambridge, UK) at an apical volume of 100 mL. After equilibration, basal CBF was determined by 10 successive measurements obtained from the same ciliated site. Growing concentrations of T2R agonists were added every 10 minutes to generate cumulative concentration response curves between $10^{-8}$ M to $10^{-3}$ M concentration.

**Pharmacomechanical experiments on human bronchi.** Segments of bronchus were dissected free from parenchymal lung tissue and preparations cut (3–4 mm length and 2–3 mm internal diameter). Preparations were used immediately for experiments. Bronchial rings were mounted in a 5 ml organ bath chamber (Pan-Lab, USA), containing Krebs-Henseleit solution (37°C), gassed with 5% CO2 in O2 at 37°C (pH 7.4), under an initial load of 1–2 g, and the isometric tension was recorded with a transducer (Grass FT03 isometric force transducer; Grass Instruments, Quincy, MA, USA) connected to a PowerLab™ data acquisition system (AD Instruments, Castle Hill, New South Wales, Australia), as we reported previously [18]. Bronchial preparations were equilibrated for 60–90 min with changes in bath Krebs-Henseleit solution every 20 min before any pharmacological intervention occurred. In all experiments, the bronchi were pre-contracted with 1 μM carbachol. After the plateau was reached, increasing concentrations of T2R agonists (chloroquine, denatonium, and saccharin) were then added for constructing concentration-response curves. After the last concentration level of T2R agonists, the maximum relaxation of each segment was evaluated by the addition of 0.1 mM papaverine.

**Statistical analysis**

Statistical analysis was performed using Prism 6 (GraphPad Software Inc, San Diego, CA, USA). Data of MCC analysis are presented as mean±SD of % radiation counts at each time point. Statistical analysis of results is carried out by analysis of variance (ANOVA) using one-way ANOVA or two-way ANOVA followed by Bonferroni test. Significance is accepted when $P<0.05$.

The concentration-response curves of T2R agonists increasing CBF and relaxing human bronchi were constructed and analyzed by non-linear regression analysis and by Student’s t test, as appropriate. The logEC50 values, defined as the concentration of drug which induces an effect equal to 50% of its own maximal effect.
Results
Measure of nasal mucociliary transport rate (NMTR) using micro-CT-SPECT albumin macroaggregates marked with Tc99m

Anesthetized guinea pig animals were undergoing drug ventilation during 10 min with different T2Rs agonists chloroquine, denatonium or saccharine at 1 mM. After drug delivery, intranasal MAA-Tc99m (100 μL; 10 mCi; particle diameter 5–90μm) particle suspension (one droplet of 25 μL) was instilled on the beginning of nasal meatus and the distance traveled by the radioisotope signal was monitored for 60 min throughout the nasal meatus cavity. Albumin macroaggregates showed a constant velocity throughout the nasal meatus with a coefficient of variability between animal measures of 7.64 ± 0.4%. The NMTR was 0.36± 0.04 mm/min in vehicle ventilated animals (Fig 1A and 1B). The treatment with T2R agonists chloroquine, denatonium and saccharin significantly increased NMTR to 0.6±0.04 mm/min, 0.66±0.02 mm/min and 0.5±0.02 mm/min respectively (Fig 1C).

Effects of T2R agonists on nasal CBF

The basal nasal CBF of untreated cells was 9.96±0.20 Hz (n = 51). The non-selective T2R agonists induced a concentration-dependent increase of CBF with a maximum increase of 30% respect the baseline (Fig 2). The rank order of potency (EC$_{50}$ values) was: diphenidol (0.05 μM), denatonium (0.96 μM), chloroquine (1.52 μM), quinine (2.89 μM) and saccharin (68.2 μM) (Fig 2). Diphenidol, denatonium, chloroquine and quinine at higher concentrations (>1 mM) caused ciliary incoordination perturbing CBF measurements. Phenanthroline was without effect.

Measure of bronchial mucociliary clearance using different micro-CT-SPECT Tc99m marked radioisotopes

Three types of Tc99m marked substances were used to evaluate bronchial MCC. First; a solution containing 10 mCi (DTPA-Tc99m) (Molipharma, Valencia, Spain) was nebulized for 15 min on a rodent nebulizer. After DTPA-Tc99m delivery, the animals were removed from the nebulizer chamber and allowed to breathe freely. Radioisotope signal was monitored throughout the lung 252 dynamic images sections obtained with the micro-CT-SPECT. Radioisotope signal showed a rapid decay because the rapid diffusion of aerosolized DTPA between the alveolar/ capillary units through the ventilation perfusion process (Fig 3A–3C). None of the T2R agonist increased bronchial MCC measures as acceleration of radioisotope signal decay (Fig 3D). SPECT images showed an irregular DTPA distribution without bronchial-tracheal expectation throughout the measured time points, which correlates with the un-particulate nature of DTPA solution which explain the lack of activity of T2R agonists. DTPA-Tc99m distribution reached extra-pulmonary locations reflecting the passage of the radioisotope from the lung to the systemic circulation (Fig 3E) after 6h of ventilation.

The second analysis of bronchial MCC was performed using MAA-Tc99m. Intratracheal instillation of MAA-Tc99m appeared patchy and centrally deposited at the earliest time point which may reflect an elevated particle size and a lack of small bronchi distribution of albumin macroaggregates (5–90μm; Fig 4). The radioisotope signal only decayed ~ 40% of the initial signal at the end of the 6h evaluation period (Fig 4). Furthermore, none of the T2R agonists increased bronchial MCC suggesting incapacity of cilia to move albumin particle. The third analysis was carried out with a suspension of Tc99m albumin nanocolloids (particle diameter ≤80nm) that was nebulized during 15 min. Inhalation of Tc99m albumin nanocolloids showed a homogeneous distribution filling up the entire lung volume (Fig 5A). Physiological MCC was
monitored by combined micro-CT and SPECT images showing continuous clearance of Tc99m albumin nanocolloids throughout the small bronchi to the tracheal section of lung reflecting the bronchial MCC in the three dimension images of the animal lungs (Fig 5B and 5C). Non-treated animals showed a rapid loss of radioisotope signal during the first 2h of inhalation followed by slow decreased signal until 6h reaching the 49.9±2% of the initial signal (Fig 6). T2R agonists accelerated the albumin nanocolloid clearance showing 28.7±1.1%, 22.5±0.24% and 38±7% of the initial signal for chloroquine, denatonium and saccharin respectively at the end of 6h period (Fig 6).

Effects of T2R agonists on human bronchi relaxation

Chloroquine, denatonium and saccharin produced a concentration-dependent relaxation of the carbachol-induced tone of human bronchi that achieve 90% to 100% of maximum relaxation induced by papaverine. The rank order of potency as bronchodilators (EC50 values) was, denatonium (50 μM), saccharin (180 μM) and chloroquine (220 μM) (Fig 7, Table 1).

The comparison of EC50 values relaxing human bronchi vs EC50 values increasing CBF for chloroquine (220 μM vs 1.52 μM) and denatonium (50 μM vs 0.96 μM) showed that potency was 100x and 50x higher stimulating ciliary motility, respectively.

Discussion

The present work evaluates micro-CT coupled-SPECT three dimension technique to measure MCC in guinea pig animals, on both, upper and lower airways which may be of potential value as a preclinical model to evaluate compromised MCC in airway diseases as well as to evaluate the effect of drugs on in vivo MCC. In this regard, we observed that T2R agonists increased MCC in vivo by a combined mechanism including the increase of CBF of epithelial ciliated cells and bronchodilation.

Various methodologies have been used to evaluate in vivo lung deposition of different substances in small animals. Gamma scintigraphy [19], X-SPECT [20], positron emission...
tomography (PET) \cite{21}, magnetic resonance Image (MRI) \cite{22} and fluorescence imaging \cite{23} can measure total lung deposition and oropharyngeal deposition of particles directly by using radionuclides non-ionizable radiation and fluorescent dye. However, to our knowledge, micro-CT coupled-SPECT technique has not been used to analyze nasal or MCC in preclinical small animals. The advantage of this technique includes a better precision of data that includes different nasal or lung section analysis (252 image slices) which produces 3D images compared to the traditional 2D image producing technique, gamma scintigraphy or X-SPECT. 3D images allow more detailed data on regional lung deposition and can monitor the trachea-bronchial release of particles or the velocity of nasal mucociliary transport since it is possible to visualize the travelled length of particles. One of the best characterized radiotracer is the DTPA-Tc99m solute that has been used to monitor ventilated lung regions to calculate ventilation/perfusion ratio \cite{24} in pulmonary embolisms, but also to study the alveolar wall integrity, nasal, tracheal and bronchial absorption and permeability \cite{25, 26}. However the utility of DTPA-Tc99m to measure MCC is under debate. While, some authors have observed that mucociliary transport mechanism does not contribute to radiotracer clearance \cite{25}, others use DTPA-Tc99m to

Fig 2. Concentration-response curves for bitter taste receptor (T2R) agonists on human nasal ciliary beat frequency CBF (Hz). CBF₀ correspond to basal values of CBF when only vehicle was added to the culture medium. Non-selective agonists (chloroquine, denatonium, quinine, saccharin and diphenidol) induced increases in CBF at the concentrations represented, with the exception of phenanthroline. The results are expressed as a mean ± SD. Two-way repeated measures analysis of variance (ANOVA): P<0.001. Post hoc Bonferroni test: *P<0.05; **P<0.01; ***P<0.001 vs CBF₀.

doi:10.1371/journal.pone.0164399.g002
measure it [27]. In the present work we observed a rapid pulmonary clearance of DTPA-Tc99m that was mediated by broncho-alveolar absorption to systemic circulation rather than MCC, since hepatic radiotracer signal capture was detected at 6h post-inhalation and no movement of tracer was detected through the tracheo-bronchial apparatus. Furthermore, the stimulation of T2R did not increase physiological DTPA-Tc99m clearance which indicates that T2R activation does not affect pulmonary permeability and that DTPA-Tc99m radiotracer is not cleared by MCC transport mechanism.

Next experiments were directed to evaluate nasal and bronchial MCC using a suspension of MAA-Tc99m (particle diameter 5–90μm). Nasal administration of MAA-Tc99m showed a
constant movement through nasal meatus at 0.36 mm/min reflecting a useful tool to monitor NMTR in vivo that has not been described previously. NMTR shows a broad variability in the literature ranging from 2.4 mm/min to 21.5 mm/min in humans [13] and 5.1 mm/min to 1.9 mm/min in rats [13]. Discrepancies observed in this work and the data reported in the literature can be explained by different techniques used, the animal species studied and also because the published work is focused in tracheal and bronchial MCC velocities but not in nasal meatus section.

In our study, the T2R agonist chloroquine and denatonium increased NMTR. Saccharin showed the lowest activity on NMTR probably because activates sweet receptors as well as T2R, so could blunt some of the bitter effects of the compound [28]. The effect of T2R agonists increasing NMTR is mediated by a direct mechanism on CBF. In fact, in isolated human nasal ciliated cells T2R activation increased CBF. Furthermore, T2R agonists can activate solitary chemosensory cells that reach the surface of the nasal epithelium and form synaptic contacts with trigeminal afferent nerve fibers [29]. Solitary chemoreceptor cells express T2R and its stimulation can induce the increase of inflammation of the nasal mucosa, the depression of respiratory rate and the increase of MCC lowering mucus viscosity in response to T2R agonists such as pseudomonas aeruginosa quorum [30–32].

In the airway, T2Rs are also expressed in bronchial smooth muscle cells of mouse [33, 34], guinea-pig [35] and human isolated airway preparations [11, 36–39] where they mediates bronchodilation. In human nose mucosa [40] have been described at least 22 types of T2Rs [41]. It has been described that these compounds augment CBF in human bronquial epithelial cells [10], but the effect on human sinonasal epithelial cells is unclear.
The T2Rs vary in their selectivity towards bitter taste compounds. Braun et al. [40] described, the following rank order expression of T2R subtypes in the human nasal respiratory mucosa: T2R5 > 4 > 3 > 31 > 10 > 14 > 13 > 46 > 43 > 39 > 7. In our study, we used non-selective T2R agonists to cover the widest range of T2R with higher expression in the human nose [40]. Most of the agonists used in the present study activated T2R3, 4, 7, 10, 13, 14, 31, 39, 43, 46 and 47. Previous observations showed that the T2R agonist denatonium stimulated calcium-dependent CBF in human bronchial ciliated cells [10]. However, Lee et al. [42] reported that application of 10 mM denatonium benzoate slowed CBF in sinonasal cells suggesting that sinonasal ciliated epithelial cells do not express functional denatonium responsive T2Rs. In this work, T2R concentration higher than 1mM caused an uncoordinated CBF which was
translated in a decrease of CBF, as observed by high speed video-microscopy, which may explain previous observations on decreased CBF as an over-activation of T2R.

In this study, the most potent T2R agonist increasing CBF was diphenidol (agonist of T2R4, 10, 14, 31, 39, and 40), followed by denatonium (T2R4, 10, and 39), chloroquine (T2R3, 10 and...
(39), quinine (T2R4, 10, 14, 31, 39, and 40) and saccharin (T2R31, 43, and 44). However, phenanthroline (selective agonist of T2R5) did not modify CBF which implicate multiple T2R subtypes, but not all, in this effect.

In contrast to nasal MCC, the use of MAA-Tc99m to measure bronchial MCC was not effective. Intratracheal instillation administered via the endotracheal route is a non-invasive aerosol pulmonary delivery technique which allows depositing particle suspensions in low airways avoiding traditional invasive surgical intratracheal administration [15]. In this work, intratracheal instillation of MAA-Tc99m appeared patchy and centrally deposited with a slow clearance that was not modified with the T2R administration, remaining ~75% of retention of MAA-Tc99m in the lung of guinea pig after 6h of instillation. As show Fig 4B, MAA-Tc99m showed a good tracheal clearance but not in bronchial tree. This phenomenon could be explained by the anatomy of guinea pig tracheo-bronchial tree which is 2100 ± 500 μm in tracheal diameter allowing a good tracheal transport. However, bronchi, bronchioles or alveolar ducts smaller diameter (100–150 μm) could retain MAA-Tc99m particles being trapped possibly by binding to the bronchial tissue.

Previous lung MCC experiments have determined that most of the particles deposited in the rat bronchial tree are cleared after about 6 to 8 h of inhalation [13]. However, other data demonstrated that intratracheal instillation particle remained with a high percentage of retention in rats when compared with nose-only aerosol inhalation [19] which may be explained by the method used for particle delivery or by the elevated particle size. In fact, the elevated particle size of the MAA-Tc99m particles, together with the incapacity of T2R to clear radiotracer, indicates the incapacity of bronchial ciliated cells to clear elevated particle size. These results are apparently contrary to that observed in nasal meatus which may be explained by the anatomical differences between the nasal cavity and bronchial tree.

In this regard, other particles suspensions joined to Tc99m have been employed to analyze MCC. Thus for example, Tc99m labeled sulfur colloid (Tc99m-SC; particle size < 100nm [43]) has been used thoroughly to evaluate MCC by means of gamma scintigraphy imaging procedure [19]. Similar results have been obtained with Tc99m albumin nanocolloids (particle diameter ≤80nm) in humans [44]. In the present work, MCC was characterized by a rapid first trachea-bronchial MCC followed by a more sustained and slow clearance of small bronchial particles [13]. Mechanism involved in lung particle clearance was attributed mostly to the MCC mechanism rather to the increase on pulmonary permeability since radiotracer particles were observed ascending from the bronchi to the trachea in a time-dependent manner. However we cannot exclude some Tc99m albumin nanocolloid pulmonary absorption to the systemic circulation. It is interesting to note that T2R agonist increased bronchial MCC at concentration that were also responsible to the increase of CBF and bronchodilation. Dual mechanism involving combination of bronchodilation and ciliary movement has been described previously for T2R agonists and could synergized increasing MCC. In chronic airway diseases such as asthma or chronic obstructive pulmonary disease (COPD), increased viscosity and mucus overproduction can end up forming mucus plugs whereby infection or localized atelectasis can be observed. Narrowing of airways combined with rubbery mucus can form

|          | Emax (%) | log EC50  | n  |
|----------|----------|-----------|----|
| Chloroquine | 91.0±2.8 | -3.66±0.05 | 8  |
| Denatonium | 96.8±1.6 | -4.31±0.13 | 7  |
| Saccharin | 98.3±1.7 | -3.74±0.44 | 9  |

doi:10.1371/journal.pone.0164399.t001
mucus plugs obstructing mucociliary clearance. In this context, bronchodilation can increase the airway diameter, and with the aid of transient increases in expiratory air flow favours that mucus trapped can be released [45].

T2R agonists have been shown to induce relaxation of airway smooth muscle in animal [11, 33, 35, 39] and human [11, 33, 36, 37] at concentrations in the range observed in this work. One limitation of these compounds as bronchodilators is their low potency [37], what limits its clinical use. The results for chloroquine, denatonium and saccharin are consistent with other studies in human bronchi, showing bronchodilation with EC$_{50}$ values in the mM range [36]. In contrast, these compounds were more potent increasing CBF, so the potency stimulating CBF for chloroquine and denatonium was 100x and 50x higher respectively. This implies that clinical effect on CBF could be achieved at lowest doses than bronchodilation. It could be difficult to understand, why EC$_{50}$ of bitter compounds for bronchodilation and CBF differ so much?. In this regard, T2R activation increases CBF through the increase of intracellular calcium in the cilia. However T2R activation induces bronchodilation through other mechanisms such as reduction in calcium oscillation by activation of calcium-activated potassium channels (BK$_{Ca}$) [11]. Also CBF system implicates a rapid diffusion of drugs to be directly in contact with cilia, unlike human ring bronchi that needs diffusion through the bronchial epithelium and basement membrane to be in contact with bronchial smooth muscle.

In summary, nasal administration of MAA-Tc99m particles monitored through the micro-CT coupled-SPECT is a useful technique to analyze in vivo NMTR, while Tc99m albumin nanocolloids are preferred to the study of low airways MCC. The use of T2R agonists in this in vivo model corroborated previous ex-vivo/ in vitro findings showing an increase of NMTR and bronchial MCC.

Supporting Information

S1 Fig. Raw data from Fig 1.
(XLSX)

S2 Fig. Raw data from Fig 2.
(XLSX)

S3 Fig. Raw data from Fig 3.
(XLSX)

S4 Fig. Raw data from Fig 4.
(XLSX)

S5 Fig. Raw data from Fig 6.
(XLSX)

S6 Fig. Raw data from Fig 7.
(XLSX)

Acknowledgments

We thanks Sonia Hervas, Adela Serrano and Ms Teresa from the Faculty of medicine of Valencia, Spain for the help carried out with the animal procedures.

Author Contributions

Conceptualization: JLO JC EM MA.
Data curation: CS EM JC.
Formal analysis: JLO JC AO JM DC.
Funding acquisition: JM EM JC.
Investigation: AO MA JM CS DC.
Methodology: AO MA JM CS DC.
Project administration: JM EM JC.
Resources: CS EM JC.
Software: CS EM JC.
Supervision: JLO JC CS JM EM.
Validation: JLO AO MA CS DC JM EM JC.
Visualization: JLO JC CS JM EM.
Writing – original draft: JLO JC CS JM EM.
Writing – review & editing: JLO JC CS JM EM.

References
1. Afzelius BA. Cilia-related diseases. J Pathol. 2004; 204:470–477. doi: 10.1002/path.1652 PMID: 15495266
2. Escudier E, Duquesnoy P, Papon JF, Amselem S. Ciliary defects and genetics of primary ciliary dyskinesia. Paediatr Respir Rev. 2009; 10:51–54. doi: 10.1016/j.prrv.2009.02.001 PMID: 19410201
3. Wang LF, White DR, Andreoli SM, Mulligan RM, Discolo CM, Schlosser RJ. Cigarette smoke inhibits dynamic ciliary beat frequency in pediatric adenoid explants. Otolaryngol Head Neck Surg. 2012; 146:659–663. doi: 10.1177/0194599811431414 PMID: 22237301
4. Boucher RC: Cystic fibrosis. A disease of vulnerability to airway surface dehydration. Trends in molecular medicine. 2007; 13:231–240. doi: 10.1016/j.molmed.2007.05.001 PMID: 17524805
5. Fahy JV, Dickey BF. Airway mucus function and dysfunction. The New England journal of medicine. 2010; 363:2233–2247. doi: 10.1056/NEJMra0910061 PMID: 21121836
6. Randell SH, Boucher RC. Effective mucus clearance is essential for respiratory health. Am J Respir Cell Mol Biol. 2006; 35:20–28. doi: 10.1165/rcomb.2006-0082SF PMID: 16528010
7. King PT. The pathophysiology of bronchiectasis. International journal of chronic obstructive pulmonary disease. 2009; 4:411–419. doi: 10.2147/COPD.S6133 PMID: 20037680
8. Munkholm M, Mortensen J. Mucociliary clearance: Pathophysiological aspects. Clinical physiology and functional imaging. 2014; 34:171–177. doi: 10.1111/cpf.12086 PMID: 24119105
9. Armengot M, Escribano A, Carda C, Basterra J. Clinical and ultrastructural correlations in nasal mucociliary function observed in children with recurrent airways infections. International journal of pediatric otorhinolaryngology. 1995; 32:143–151. doi: 10.1016/0165-5876(95)01133-V PMID: 7657468
10. Shah AS, Ben-Shahar Y, Moninger TO, Kiene JN, Welsh MJ. Motile cilia of human airway epithelia are chemosensory. Science. 2009; 325:1131–1134. doi: 10.1126/science.1166869 PMID: 19628819
11. Deshpande DA, Wang WC, McIlmoyle EL, Robinett KS, Schillinger RM, An SS, et al. Bitter taste receptors on airway smooth muscle bronchodilate by localized calcium signaling and reverse obstruction. Nature medicine. 2010; 16:1299–1304. doi: 10.1038/nm.2237 PMID: 20972434
12. Brewer NR, Cruise LJ. The respiratory system of the guinea pig: Emphasis on species differences. Contemporary topics in laboratory animal science / American Association for Laboratory Animal Science. 1997; 36:100–108. PMID: 12456198
13. Hofmann W, Asgharian B. The effect of lung structure on mucociliary clearance and particle retention in human and rat lungs. Toxicological sciences: an official journal of the Society of Toxicology. 2003; 73:448–456. doi: 10.1093/toxsci/kf075 PMID: 12700392
14. Almudever P, Milara J, De Diego A, Serrano-Mollar A, Xaubet A, Perez-Vizcaino F, et al. Role of tetrahydrobiopterin in pulmonary vascular remodelling associated with pulmonary fibrosis. Thorax. 2013; 68:938–948. doi: 10.1136/thoraxjnl-2013-203408 PMID: 23791937

15. Bivas-Benita M, Zwier R, Junginger HE, Borchard G. Non-invasive pulmonary aerosol delivery in mice by the endotracheal route. European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2005; 61:214–218. doi: 10.1016/j.ejpb.2005.04.009 PMID: 16039104

16. Armengot M, Milara J, Mata M, Carda C, Cortijo J. Cilia motility and structure in primary and secondary ciliary dyskinesia. Am J Rhinol Allergy. 2010; 24:175–180. doi: 10.2500/ajra.2010.24.3448 PMID: 20537282

17. Milara J, Armengot M, Banuls P, Tenor H, Beume R, Artigues E, et al. Roflumilast n-oxide, a pde4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro. British journal of pharmacology. 2012; 166:2243–2262. doi: 10.1111/j.1476-5381.2012.01929.x PMID: 22385203

18. Ballester C, Sarria B, Garcia-Granero E, Morcillo EJ, Lledo S, Cortijo J. Relaxation of the isolated human internal anal sphincter by sildenafil. The British journal of surgery. 2007; 94:894–902. doi: 10.1002/bjs.5724 PMID: 17339124

19. Foster WM, Walters DM, Longphre M, Macri K, Miller LM. Methodology for the measurement of mucociliary function in the mouse by scintigraphy. Journal of applied physiology. 2001; 90:1111–1117. PMID: 11181627

20. Bhashyam AR, Mogayzel PJ Jr., Cleary JC, Undem BJ, Kollarik M, Fox J, et al. Vagal control of mucociliary function in the mouse by scintigraphy. In vivo. 2010; 24:175–180. doi: 10.2500/ajra.2010.24.3448 PMID: 20537282

21. Yi D, Wiedmann TS, Naqwi A, Price AP, Panoskaltsis-Mortari A. Distribution of aerosols in murine bronchial airways. Thorax. 1990; 45:841–845. doi: 10.1136/thx.45.11.841 PMID: 22560111

22. Bla Feld FX, Cannet C, Collingwood S, Danahay H, Beckmann N. Enac-mediated effects assessed by mri perfusion scintigraphy performed for the indication of pulmonary embolism: Us practice survey. Clinical nuclear medicine. 2015; 40:553–558. doi: 10.1097/RNU.0000000000000763 PMID: 25899592

23. Yi D, Wiedmann TS, Naqwi A, Price AP, Panoskaltsis-Mortari A. Distribution of aerosols in murine obliterative bronchiolitis lungs by fluorescent imaging. Experimental lung research. 2012; 38:325–332. doi: 10.3109/01902148.2012.700760 PMID: 22741919

24. Opanowski A, Gross LJ, Tulchinsky M. Radiopharmaceutical options for the ventilation part of ventilation-perfusion scintigraphy performed for the indication of pulmonary embolism: Us practice survey. Clinical nuclear medicine. 2015; 40:553–558. doi: 10.1097/RNU.0000000000000763 PMID: 25899592

25. Greiff L, Wollmer P, Erjefalt I, Pipkorn U, Persson CG. Clearance of 99mtc dtpa from guinea pig nasal, tracheobronchial, and bronchoalveolar airways. Thorax. 1990; 45:841–845. doi: 10.1136/thx.45.11.841 PMID: 22560111

26. Wu Y, Kotzer CJ, Makrogiannis S, Logan GA, Harnette MS, et al. A noninvasive [99mtc]dtpa spect/ct imaging methodology as a measure of lung permeability in a guinea pig model of copd. Molecular imaging and biology: MIB: the official publication of the Academy of Molecular Imaging. 2011; 13:923–929. doi: 10.1007/s11307-010-0423-9 PMID: 20838995

27. Karacavus S, Intepe YS. The role of tc-99m dtpa aerosol scintigraphy in the differential diagnosis of copd and asthma. The clinical respiratory journal. 2015; 9:189–195. doi: 10.1111/crj.12123 PMID: 24520880

28. Tizzano M, Cristofoletti M, Sbarbati A, Finger TE. Expression of taste receptors in solitary chemosensory cells of rodent airways. BMC pulmonary medicine. 2011; 11:3. doi: 10.1186/1471-2466-11-3 PMID: 21232137

29. Finger TE, Bottger B, Andersen KT, Alamohammad H, Silver WL. Solitary chemoreceptor cells in the nasal cavity serve as sentinels of respiration. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100:8981–8986. doi: 10.1073/pnas.1531172100 PMID: 12857948

30. Krasteva G, Canning BJ, Papadakis T, Kummer W. Cholinergic brush cells in the trachea mediate respiratory responses to quorum sensing molecules. Life sciences. 2012; 91:992–996. doi: 10.1016/j.lfs.2012.06.014 PMID: 22749863

31. Saunders CJ, Christensen M, Finger TE, Tizzano M. Cholinergic neurotransmission links solitary chemosensory cells to nasal inflammation. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111:6075–6080. doi: 10.1073/pnas.1402251111 PMID: 24711432

32. Tizzano M, Gulbransen BD, Vandenbeuch A, Clapp TR, Herman JP, Sibhatu HM, et al. Nasal chemosensory cells use bitter taste signaling to detect irritants and bacterial signals. Proceedings of the
33. Zhang CH, Lifshitz LM, Uy KF, Ikebe M, Fogarty KE, ZhuGe R. The cellular and molecular basis of bitter tastant-induced bronchodilation. PLoS biology. 2013; 11:e1001501. doi: 10.1371/journal.pbio.1001501 PMID: 23472053

34. Tan X, Sanderson MJ. Bitter tasting compounds dilate airways by inhibiting airway smooth muscle calcium oscillations and calcium sensitivity. British journal of pharmacology. 2014; 171:646–662. doi: 10.1111/bph.12460 PMID: 24117140

35. Pulkkinen V, Manson ML, Satholm J, Adner M, Dahlen SE. The bitter taste receptor (tas2r) agonists denatonium and chloroquine display distinct patterns of relaxation of the guinea pig trachea. American journal of physiology Lung cellular and molecular physiology. 2012; 303:L956–966. doi: 10.1152/japplung.00205.2012 PMID: 22962016

36. Grassin-Delyle S, Abrial C, Fayad-Kobeissi S, Brollo M, Faisy C, Alvarez JC, Naline E, et al. The expression and relaxant effect of bitter taste receptors in human bronchi. Respiratory research. 2013; 14:134. doi: 10.1186/1465-9921-14-134 PMID: 24266887

37. Belvisi MG, Dale N, Birrell MA, Canning BJ. Bronchodilator activity of bitter tastants in human tissue. Nature medicine. 2011; 17:776; author reply 776–778. doi: 10.1038/nm.21738151

38. Morice AH, Bennett RT, Chaudhry MA, Cowen ME, Griffin SC, Loubani M. Effect of bitter tastants on human bronchi. Nature medicine. 2011; 17:775. doi: 10.1038/nm.21738149

39. Zhang CH, Chen C, Lifshitz LM, Fogarty KE, Zhu MS, ZhuGe R. Activation of bk channels may not be required for bitter tastant-induced bronchodilation. Nature medicine. 2012; 18:648–650; author reply 650–641. doi: 10.1038/nm.22561814

40. Braun T, Mack B, Kramer MF. Solitary chemosensory cells in the respiratory and vomeronasal epithelium of the human nose: A pilot study. Rhinology. 2011; 49:507–512. doi: 10.4193/Rhino11.121 PMID: 22125779

41. Meyerhof W, Batram C, Kuhn C, Brockhoff A, Chudoba E, Bufe B, et al. The molecular receptive ranges of human tas2r bitter taste receptors. Chemical senses. 2010; 35:157–170. doi: 10.1093/chemse/bjp092 PMID: 20022913

42. Lee RJ, Kofonow JM, Rosen PL, Siebert AP, Chen B, Doghramji L, et al. Bitter and sweet taste receptors regulate human upper respiratory innate immunity. The Journal of clinical investigation. 2014; 124:1399–1405. doi: 10.1172/JCI72094 PMID: 24531552

43. Hung JC, Wiseman GA, Wahner HW, Mullan BP, Taggart TR, Dunn WL. Filtered technetium-99m-sulfur colloid evaluated for lymphoscintigraphy. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 1995; 36:1895–1901. PMID: 7562061

44. Fleming J, Conway J, Majoral C, Tossici-Bolt L, Katz I, Caillibotte G, et al. The use of combined single photon emission computed tomography and x-ray computed tomography to assess the fate of inhaled aerosol. Journal of aerosol medicine and pulmonary drug delivery. 2011; 24:49–60. doi: 10.1089/jamp.2010.0843 PMID: 21166585

45. Volsko TA. Airway clearance therapy: Finding the evidence. Respiratory care. 2013; 58:1669–1678. doi: 10.4187/respcare.02590 PMID: 24064626